Boyd Matthew Ross 4

What Happened
Boyd Matthew Ross, Chief Regulatory Officer of enGene Holdings, was granted a derivative award of 195,000 shares (reported at $0.00) on January 30, 2026. The Form 4 lists this as an award/grant (transaction code A); the filing reports a total reported value of $0 for the grant.

Key Details

• Transaction date: 2026-01-30. Form 4 filed: 2026-02-03 (timely).
• Transaction type/code: Grant/Award (A) of a derivative (option) for 195,000 shares, reported price $0.00, reported value $0.
• Vesting: Footnote F1 — the option vests monthly in substantially equal amounts over 48 months, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• No tax-withholding, 10b5-1 plan, or sale/exercise noted in this report.

Context
This is a time-based option award intended as a retention/incentive grant; it is not an open-market purchase or a sale and does not reflect immediate cash proceeds. Awards are common compensation for executives and should be read as a long-term incentive rather than a near-term market signal.